Drug Type Small molecule drug |
Synonyms AGX-201 |
Target- |
Action- |
Mechanism- |
Therapeutic Areas |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization- |
License Organization- |
Drug Highest PhasePhase 2 |
First Approval Date- |
Regulation- |
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Migraine Disorders | Phase 2 | United States | 09 Oct 2022 | |
| Acute migraine | Phase 2 | - | 01 Oct 2022 | |
| Migraine Without Aura | Phase 2 | - | 01 Oct 2022 | |
| Amyotrophic Lateral Sclerosis 11 | Phase 1 | United States | 09 Oct 2022 | |
| Attention Deficit Disorder With Hyperactivity | Phase 1 | United States | 09 Oct 2022 | |
| Chronic Traumatic Encephalopathy | Phase 1 | United States | 09 Oct 2022 | |
| Epilepsy | Phase 1 | United States | 09 Oct 2022 | |
| Multiple Sclerosis | Phase 1 | United States | 09 Oct 2022 | |
| Parkinson Disease | Phase 1 | United States | 09 Oct 2022 | |
| Schizophrenia | Phase 1 | United States | 09 Oct 2022 |





